Mostrar el registro sencillo del ítem
dc.contributor.author | Mazagatos, Clara | |
dc.contributor.author | Delgado-Sanz, Concepcion | |
dc.contributor.author | Monge Corella, Susana | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Oliva, Jesús | |
dc.contributor.author | Sandonis-Martin, Virginia | |
dc.contributor.author | Gandarillas, Ana | |
dc.contributor.author | Quiñones-Rubio, Carmen | |
dc.contributor.author | Ruiz-Sopeña, Cristina | |
dc.contributor.author | Gallardo-García, Virtudes | |
dc.contributor.author | Basile, Luca | |
dc.contributor.author | Barranco-Boada, María Isabel | |
dc.contributor.author | Hidalgo-Pardo, Olga | |
dc.contributor.author | Vazquez-Cancela, Olalla | |
dc.contributor.author | García-Vázquez, Miriam | |
dc.contributor.author | Fernández-Sierra, Amelia | |
dc.contributor.author | Milagro-Beamonte, Ana | |
dc.contributor.author | Ordobás, María | |
dc.contributor.author | Martínez-Ochoa, Eva | |
dc.contributor.author | Fernández-Arribas, Socorro | |
dc.contributor.author | Lorusso, Nicola | |
dc.contributor.author | Martínez, Ana | |
dc.contributor.author | García-Fulgueiras, Ana | |
dc.contributor.author | Sastre-Palou, Bartolomé | |
dc.contributor.author | Losada-Castillo, Isabel | |
dc.contributor.author | Martínez-Cuenca, Silvia | |
dc.contributor.author | Rodríguez-Del Águila, Mar | |
dc.contributor.author | Latorre, Miriam | |
dc.contributor.author | Larrauri, Amparo | |
dc.contributor.author | SARI surveillance VE group in Spain | |
dc.contributor.author | Casas Flecha, Inmaculada | |
dc.contributor.author | Vazquez-Moron, Sonia | |
dc.contributor.author | La Montaña Iglesias Caballero, María de | |
dc.date.accessioned | 2023-02-07T11:51:05Z | |
dc.date.available | 2023-02-07T11:51:05Z | |
dc.date.issued | 2022-11 | |
dc.identifier.citation | Influenza Other Respir Viruses. 2022 Nov;16(6):1014-1025. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15462 | |
dc.description.abstract | Background: With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a new syndromic sentinel surveillance system. The Acute Respiratory Infection Surveillance System (SiVIRA in Spanish) is based on a sentinel network for acute respiratory infection (ARI) surveillance in primary care and a network of sentinel hospitals for severe ARI (SARI) surveillance in hospitals. Methods: Using a test-negative design and data from SARI admissions notified to SiVIRA between January 1 and October 3, 2021, we estimated COVID-19 vaccine effectiveness (VE) against hospitalization, by age group, vaccine type, time since vaccination, and SARS-CoV-2 variant. Results: VE was 89% (95% CI: 83-93) against COVID-19 hospitalization overall in persons aged 20 years and older. VE was higher for mRNA vaccines, and lower for those aged 80 years and older, with a decrease in protection beyond 3 months of completing vaccination, and a further decrease after 5 months. We found no differences between periods with circulation of Alpha or Delta SARS-CoV-2 variants, although variant-specific VE was slightly higher against Alpha. Conclusions: The SiVIRA sentinel hospital surveillance network in Spain was able to describe clinical and epidemiological characteristics of SARI hospitalizations and provide estimates of COVID-19 VE in the population under surveillance. Our estimates add to evidence of high effectiveness of mRNA vaccines against severe COVID-19 and waning of protection with time since vaccination in those aged 80 or older. No substantial differences were observed between SARS-CoV-2 variants (Alpha vs. Delta). | es_ES |
dc.description.sponsorship | The data of the study was originally collectedas part of the following projects run by the European Centre for Disease Prevention and Control:“Establishing Severe Acute Respiratory Infections (SARI) surveillance and performing hospital-based COVID-19 transmission studies”, “Developing an infrastructure and performing vaccine effectiveness studies for COVID-19 vaccines in the EU/EEA”, and the “Vaccine Effectiveness, Burden and Impact Studies(VEBIS) of COVID-19 and Influenza". | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | COVID-19 vaccine | es_ES |
dc.subject | SARI surveillance | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Spain | es_ES |
dc.subject | Test-negative design | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Respiratory Tract Infections | es_ES |
dc.subject.mesh | COVID-19 Vaccines | es_ES |
dc.subject.mesh | Hospitalization | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | SARS-CoV-2 | es_ES |
dc.subject.mesh | Sentinel Surveillance | es_ES |
dc.subject.mesh | Spain | es_ES |
dc.subject.mesh | Vaccine Efficacy | es_ES |
dc.title | COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35880469 | es_ES |
dc.format.volume | 16 | es_ES |
dc.format.number | 6 | es_ES |
dc.format.page | 1014-1025 | es_ES |
dc.identifier.doi | 10.1111/irv.13026 | es_ES |
dc.contributor.funder | Unión Europea. European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1750-2659 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1111/irv.13026 | es_ES |
dc.identifier.journal | Influenza and other respiratory viruses | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |